糖尿病性黄斑水肿的药物治疗进展

被引：11

作者：

康皓

徐延山

张红

苏龙

机构：

[1] 天津医科大学眼科中心

来源：

中华眼底病杂志 | 2010年 / 02期

关键词：

糖尿病视网膜病变/治疗; 黄斑水肿/药物疗法; 综述文献;

D O I：

暂无

中图分类号：

R774.5 [黄斑、中心窝疾病]; R587.2 [糖尿病性昏迷及其他并发症];

学科分类号：

100212 ; 1002 ; 100201 ;

摘要：

糖尿病性黄斑水肿(DME)是导致糖尿病视网膜病变(DR)患者视力下降的主要原因之一。目前,激光光凝和玻璃体手术治疗已经明显降低了DR的致盲率,但二者对于改善视力的疗效、特别是对于糖尿病性黄斑水肿的疗效尚不能令人满意。随着对DR发病机制的深入研究,目前已开发出多种药物用于防治DR,特别是在治疗DME方面取得了一定的疗效,包括糖皮质激素、抗血管内皮生长因子药物、非甾体类药物、降血脂药物、血管紧张素抑制剂和选择性蛋白激酶C-β抑制剂。本文就近几年来药物治疗糖尿病性黄斑水肿的进展作一综述。

引用

共 18 条

[1] A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema [J].

Ip, Michael S. ;

Edwards, Allison R. ;

Beck, Roy W. ;

Bressler, Neil M. ;

Aiello, Lloyd Paul ;

Browning, David J. ;

Elman, Michael J. ;

Friedman, Scott M. ;

Ferris, Frederick L. ;

Glassman, Adam R. ;

Kollman, Craig ;

Price, Angela .

OPHTHALMOLOGY, 2008, 115 (09) :1447-1459

[2]

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy （FIELD study）: a randomised controlled trial[J] . AC Keech,P Mitchell,PA Summanen,J O’Day,TME Davis,MS Moffitt,M-R Taskinen,RJ Simes,D Tse,E Williamson,A Merrifield,LT Laatikainen,MC d’Emden,DC Crimet,RL O’Connell,PG Colman.The Lancet . 2007 (9600)

[3] Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes [J].

Sugiyama, Tetsuya ;

Okuno, Takashi ;

Fukuhara, Masayuki ;

Oku, Hidehiro ;

Ikeda, Tsunehiko ;

Obayashi, Hiroshi ;

Ohta, Mitsuhiro ;

Fukui, Michiaki ;

Hasegawa, Goji ;

Nakamura, Naoto .

EXPERIMENTAL EYE RESEARCH, 2007, 85 (03) :406-412

[4]

Primary Intravitreal Bevacizumab （Avastin） for Diabetic Macular Edema[J] . J. Fernando Arevalo,Jans Fromow-Guerra,Hugo Quiroz-Mercado,Juan G. Sanchez,Lihteh Wu,Mauricio Maia,Maria H. Berrocal,Adriana Solis-Vivanco,Michel E. Farah.Ophthalmology . 2007 (4)

[5] The therapeutic potential of VEGF inhibition in diabetic microvascular complications [J].

Tremolada, Gemma ;

Lattanzio, Rosangela ;

Mazzolari, Gabriella ;

Zerbini, Gianpaolo .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (06) :393-398

[6] A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema [J].

Scott, Ingrid U. ;

Edwards, Allison R. ;

Beck, Roy W. ;

Bressler, Neil M. ;

Chan, Clement K. ;

Elman, Michael J. ;

Friedman, Scott M. ;

Greven, Craig Michael ;

Maturi, Raj K. ;

Pieramici, Dante J. ;

Shami, Michel ;

Singerman, Lawrence J. ;

Stockdale, Cynthia R. .

OPHTHALMOLOGY, 2007, 114 (10) :1860-1867

[7] Vascular endothelial growth factor is a critical stimulus for diabetic macular edema [J].

Nguyen, Quan Dong ;

Tatlipinar, Sinan ;

Shah, Syed Mahmood ;

Haller, Julia A. ;

Quinlan, Edward ;

Sung, Jennifer ;

Zimmer-Galler, Ingrid ;

Do, Diana V. ;

Campochiaro, Peter A. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (06) :961-969

[8] A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema [J].

Chun, Dal W. ;

Heier, Jeffrey S. ;

Topping, Trexler M. ;

Duker, Jay S. ;

Bankert, Joy M. .

OPHTHALMOLOGY, 2006, 113 (10) :1706-1712

[9] A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration [J].

Nguyen, Quan Dong ;

Shah, Syed Mahmood ;

Hafiz, Gulnar ;

Quinlan, Edward ;

Sung, Jennifer ;

Chu, Karen ;

Cedarbaum, Jesse M. ;

Campochiaro, Peter A. .

OPHTHALMOLOGY, 2006, 113 (09) :1522-1532

[10]

Glucocorticoid Regulation of Endothelial Cell Tight Junction Gene Expression: Novel Treatments for Diabetic Retinopathy[J] . Edward A. Felinski,David A. Antonetti.Current Eye Research . 2005 (11)

← 1 2 →